LncRNA PVT1 promotes proliferation, migration and invasion of cholangiocarcinoma by regulating the expression of...

Cholangiocarcinoma, a malignant tumor originating from the bile duct epithelium, poses significant therapeutic challenges and is often associated with poor prognosis. This study aims to elucidate the relationship between plasmacytoma variant translocation 1 (PVT1), a long non-coding RNA implicated in cancer progression, and suppressor of cytokine signaling 2 (SOCS2), recognized for its tumor-suppressive properties. Utilizing the GEPIA2 database, we investigated the expression levels of PVT1 and SOCS2 in cholangiocarcinoma specimens and cell lines through quantitative real-time PCR (qRT-PCR) and Western blotting. Our results demonstrated that PVT1 expression was markedly upregulated in cholangiocarcinoma tissues and cells, while SOCS2 was significantly downregulated. Functional assays revealed that silencing PVT1 inhibited cholangiocarcinoma cell proliferation, migration, and invasion, suggesting its oncogenic role. Conversely, SOCS2 overexpression diminished these malignancies, highlighting its tumor-suppressive function. Notably, the knockdown of PVT1 correlated with an increase in SOCS2 expression, underscoring the regulatory interplay between these two molecules. Ultimately, our findings indicate that lncRNA PVT1 facilitates cholangiocarcinoma progression by repressing SOCS2 expression, positioning SOCS2 as a potential therapeutic target, and warranting further exploration in therapeutic strategies against cholangiocarcinoma.